Global Pharmaceutical Logistics Market Forecast 2024-2032

The global pharmaceutical logistics market is estimated to progress at a CAGR of 7.56% during the forecast period 2024-2032. Numerous aspects boost the market growth: the rising need for temperature-controlled solutions in pharmaceuticals, the expansion of ocean freight services in the pharmaceutical industry, the rise in consumer preference for over-the-counter medicines, and the surge in pharmaceutical logistics during the global COVID-19 pandemic.

MARKET INSIGHTS

The global pharmaceutical logistics market is experiencing substantial growth driven by several key factors. One significant driver is the increasing demand for pharmaceutical products globally, fueled by factors such as population growth, aging demographics, and rising healthcare expenditures. The heightened demand for pharmaceutical products necessitates efficient and reliable logistics solutions. These solutions are crucial for ensuring the timely delivery and proper handling of pharmaceutical goods, including temperature-sensitive medications and vaccines.

Technological advancements play a crucial role in shaping the pharmaceutical logistics landscape. Innovations such as IoT (Internet of Things), AI (Artificial Intelligence), and blockchain are revolutionizing supply chain management, enabling real-time tracking, temperature monitoring, and improved transparency. These technologies enhance efficiency and reduce errors in pharmaceutical logistics operations. They also ensure compliance with regulatory requirements, contributing to the overall growth and effectiveness of such operations globally.

Moreover, the COVID-19 pandemic has further highlighted the importance of robust pharmaceutical logistics networks. The rapid development and distribution of vaccines, along with the increased demand for critical healthcare supplies, underscore the need for agile and resilient logistics systems. As the pharmaceutical industry evolves and expands, the logistics sector must adapt to meet dynamic market demands. This adaptation fosters innovation and investment in advanced logistics solutions to address the challenges of a globalized market.

REGIONAL INSIGHTS

The global pharmaceutical logistics market growth analysis includes the geographical assessment of Asia-Pacific, Europe, North America, and Rest of World. Europe was the largest region in the global pharmaceutical logistics market. The heightened demand for pharmaceutical logistics in Europe stems from the increased requirement for vaccines and medications driven by the COVID-19 pandemic. Companies are emphasizing reducing costs and providing swift assistance, which is propelling the market's growth further.

COMPETITIVE INSIGHTS

The global pharmaceutical logistics market is characterized by intense rivalry among key players, driving competitive strategies such as cost leadership, differentiation, and strategic partnerships. Companies constantly innovate to improve service offerings, optimize supply chain operations, and expand market reach amidst dynamic market conditions. Some of the eminent players in the market include Agility Logistics, AP Moller - Maersk, Cardinal Health, Cencora (AmerisourceBergen), CEVA Logistics, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 85233

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON PHARMACEUTICAL LOGISTICS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. BRANDED DRUGS ARE THE MOST COMMONLY USED PRODUCTS IN THE PHARMACEUTICAL LOGISTICS MARKET
- 2.5.2. COMMUNICABLE DISEASES HOLD THE LARGEST MARKET SHARE IN THE THERAPY AREA
- 2.5.3. COLD CHAIN LOGISTICS IS THE FASTEST-GROWING TYPE WITHIN THE PHARMACEUTICAL LOGISTICS MARKET
- 2.5.4. MONITORING OF PHARMACEUTICAL LOGISTICS OPERATIONS IS INCREASINGLY BECOMING A FOCUS AREA

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING NEED FOR TEMPERATURE-CONTROLLED SOLUTIONS IN PHARMACEUTICALS
- 3.1.2. EXPANSION OF OCEAN FREIGHT SERVICES IN PHARMACEUTICAL INDUSTRY
- 3.1.3. RISE IN CONSUMER PREFERENCE FOR OVER-THE-COUNTER MEDICINES
- 3.1.4. SURGE IN PHARMACEUTICAL LOGISTICS DURING THE GLOBAL COVID-19 PANDEMIC
3.2. KEY RESTRAINTS
- 3.2.1. RIGOROUS REGULATORY REQUIREMENTS IN PHARMACEUTICAL LOGISTICS
- 3.2.2. ENSURING REAL-TIME TRANSPARENCY AND RELIABILITY IN PHARMACEUTICAL LOGISTICS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. SURGE IN DEMAND FOR CELL & GENE THERAPY LOGISTICS
- 4.1.2. REVOLUTIONIZING PHARMACEUTICAL LOGISTICS THROUGH DIGITAL TRANSFORMATION
- 4.1.3. INCREASING CLINICAL TRIALS LOGISTICS DEMANDS
4.2. PORTER'S FIVE FORCES ANALYSIS
- 4.2.1. BUYERS POWER
- 4.2.2. SUPPLIERS POWER
- 4.2.3. SUBSTITUTION
- 4.2.4. NEW ENTRANTS
- 4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
- 4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
- 4.3.2. GROWTH PROSPECT MAPPING FOR GERMANY
- 4.3.3. GROWTH PROSPECT MAPPING FOR INDIA
- 4.3.4. GROWTH PROSPECT MAPPING FOR JAPAN
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
- 4.6.1. MANUFACTURING
- 4.6.2. STORAGE
- 4.6.3. TRANSPORTATION
- 4.6.4. DISTRIBUTION
- 4.6.5. MONITORING COMPONENTS
- 4.6.6. CONSUMPTION
4.7. REGULATORY FRAMEWORK
- 4.7.1. THE DRUG SUPPLY CHAIN SECURITY ACT
- 4.7.2. THE FALSE MEDICINES DIRECTIVE (FMD)
- 4.7.3. BRAZIL'S SERIALIZATION AND DIGITAL LEAFLETS
- 4.7.4. GOOD MANUFACTURING PRACTICE (GMP), GOOD DISTRIBUTION PRACTICE (GDP), AND GOOD WAREHOUSING PRACTICE (GWP)
4.8. KEY BUYING CRITERIA
- 4.8.1. TYPE OF LOGISTICS
- 4.8.2. SERVICES OFFERED
- 4.8.3. MODE OF TRANSPORTATION
- 4.8.4. APPLICATION
- 4.8.5. REGULATORY COMPLIANCE
- 4.8.6. TECHNOLOGICAL CAPABILITIES
- 4.8.7. COST
- 4.8.8. RELIABILITY
- 4.8.9. AGILITY

5. MARKET BY PRODUCT

5.1. BRANDED DRUGS
- 5.1.1. MARKET FORECAST FIGURE
- 5.1.2. SEGMENT ANALYSIS
5.2. GENERIC DRUGS
- 5.2.1. MARKET FORECAST FIGURE
- 5.2.2. SEGMENT ANALYSIS
5.3. OTC
- 5.3.1. MARKET FORECAST FIGURE
- 5.3.2. SEGMENT ANALYSIS

6. MARKET BY THERAPY AREA

6.1. COMMUNICABLE DISEASES
- 6.1.1. MARKET FORECAST FIGURE
- 6.1.2. SEGMENT ANALYSIS
6.2. ONCOLOGY
- 6.2.1. MARKET FORECAST FIGURE
- 6.2.2. SEGMENT ANALYSIS
6.3. DIABETES
- 6.3.1. MARKET FORECAST FIGURE
- 6.3.2. SEGMENT ANALYSIS
6.4. CARDIOVASCULAR DISEASES
- 6.4.1. MARKET FORECAST FIGURE
- 6.4.2. SEGMENT ANALYSIS
6.5. AUTOIMMUNE DISEASES
- 6.5.1. MARKET FORECAST FIGURE
- 6.5.2. SEGMENT ANALYSIS
6.6. NEUROLOGICAL DISORDERS
- 6.6.1. MARKET FORECAST FIGURE
- 6.6.2. SEGMENT ANALYSIS
6.7. PAIN MANAGEMENT
- 6.7.1. MARKET FORECAST FIGURE
- 6.7.2. SEGMENT ANALYSIS
6.8. RESPIRATORY DISEASES
- 6.8.1. MARKET FORECAST FIGURE
- 6.8.2. SEGMENT ANALYSIS
6.9. OTHER THERAPY AREAS
- 6.9.1. MARKET FORECAST FIGURE
- 6.9.2. SEGMENT ANALYSIS

7. MARKET BY TYPE

7.1. NON-COLD CHAIN LOGISTICS
- 7.1.1. MARKET FORECAST FIGURE
- 7.1.2. SEGMENT ANALYSIS
7.2. COLD CHAIN LOGISTICS
- 7.2.1. MARKET FORECAST FIGURE
- 7.2.2. SEGMENT ANALYSIS

8. MARKET BY COMPONENT

8.1. STORAGE
- 8.1.1. WAREHOUSE
  - 8.1.1.1. MARKET FORECAST FIGURE
  - 8.1.1.2. SEGMENT ANALYSIS
- 8.1.2. REFRIGERATED CONTAINERS
  - 8.1.2.1. MARKET FORECAST FIGURE
  - 8.1.2.2. SEGMENT ANALYSIS
8.2. TRANSPORTATION
- 8.2.1. OVERLAND LOGISTICS
  - 8.2.1.1. MARKET FORECAST FIGURE
  - 8.2.1.2. SEGMENT ANALYSIS
- 8.2.2. SEA FREIGHT LOGISTICS
  - 8.2.2.1. MARKET FORECAST FIGURE
  - 8.2.2.2. SEGMENT ANALYSIS
- 8.2.3. AIR FREIGHT LOGISTICS
  - 8.2.3.1. MARKET FORECAST FIGURE
  - 8.2.3.2. SEGMENT ANALYSIS
8.3. MONITORING COMPONENTS
- 8.3.1. HARDWARE
  - 8.3.1.1. SENSORS
  - 8.3.1.1.1. MARKET FORECAST FIGURE
  - 8.3.1.1.2. SEGMENT ANALYSIS
  - 8.3.1.2. RFID DEVICES
  - 8.3.1.2.1. MARKET FORECAST FIGURE
  - 8.3.1.2.2. SEGMENT ANALYSIS
  - 8.3.1.3. TELEMATICS
  - 8.3.1.3.1. MARKET FORECAST FIGURE
  - 8.3.1.3.2. SEGMENT ANALYSIS
  - 8.3.1.4. NETWORKING DEVICES
  - 8.3.1.4.1. MARKET FORECAST FIGURE
  - 8.3.1.4.2. SEGMENT ANALYSIS
- 8.3.2. SOFTWARE
  - 8.3.2.1. MARKET FORECAST FIGURE
  - 8.3.2.2. SEGMENT ANALYSIS

9. GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. NORTH AMERICA PHARMACEUTICAL LOGISTICS MARKET DRIVERS
- 9.1.3. NORTH AMERICA PHARMACEUTICAL LOGISTICS MARKET CHALLENGES
- 9.1.4. KEY PLAYERS IN NORTH AMERICA PHARMACEUTICAL LOGISTICS MARKET
- 9.1.5. COUNTRY ANALYSIS
  - 9.1.5.1. UNITED STATES
  - 9.1.5.1.1. UNITED STATES PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.1.5.2. CANADA
  - 9.1.5.2.1. CANADA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
9.2. EUROPE
- 9.2.1. MARKET SIZE & ESTIMATES
- 9.2.2. EUROPE PHARMACEUTICAL LOGISTICS MARKET DRIVERS
- 9.2.3. EUROPE PHARMACEUTICAL LOGISTICS MARKET CHALLENGES
- 9.2.4. KEY PLAYERS IN EUROPE PHARMACEUTICAL LOGISTICS MARKET
- 9.2.5. COUNTRY ANALYSIS
  - 9.2.5.1. GERMANY
  - 9.2.5.1.1. GERMANY PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.2. UNITED KINGDOM
  - 9.2.5.2.1. UNITED KINGDOM PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.3. FRANCE
  - 9.2.5.3.1. FRANCE PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.4. ITALY
  - 9.2.5.4.1. ITALY PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.5. SPAIN
  - 9.2.5.5.1. SPAIN PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.6. BELGIUM
  - 9.2.5.6.1. BELGIUM PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.7. POLAND
  - 9.2.5.7.1. POLAND PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.2.5.8. REST OF EUROPE
  - 9.2.5.8.1. REST OF EUROPE PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
9.3. ASIA-PACIFIC
- 9.3.1. MARKET SIZE & ESTIMATES
- 9.3.2. ASIA-PACIFIC PHARMACEUTICAL LOGISTICS MARKET DRIVERS
- 9.3.3. ASIA-PACIFIC PHARMACEUTICAL LOGISTICS MARKET CHALLENGES
- 9.3.4. KEY PLAYERS IN ASIA-PACIFIC PHARMACEUTICAL LOGISTICS MARKET
- 9.3.5. COUNTRY ANALYSIS
  - 9.3.5.1. CHINA
  - 9.3.5.1.1. CHINA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.2. JAPAN
  - 9.3.5.2.1. JAPAN PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.3. INDIA
  - 9.3.5.3.1. INDIA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.4. AUSTRALIA & NEW ZEALAND
  - 9.3.5.4.1. AUSTRALIA & NEW ZEALAND PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.5. SOUTH KOREA
  - 9.3.5.5.1. SOUTH KOREA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.6. THAILAND
  - 9.3.5.6.1. THAILAND PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.7. INDONESIA
  - 9.3.5.7.1. INDONESIA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.8. VIETNAM
  - 9.3.5.8.1. VIETNAM PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.3.5.9. REST OF ASIA-PACIFIC
  - 9.3.5.9.1. REST OF ASIA-PACIFIC PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
9.4. REST OF WORLD
- 9.4.1. MARKET SIZE & ESTIMATES
- 9.4.2. REST OF WORLD PHARMACEUTICAL LOGISTICS MARKET DRIVERS
- 9.4.3. REST OF WORLD PHARMACEUTICAL LOGISTICS MARKET CHALLENGES
- 9.4.4. KEY PLAYERS IN REST OF WORLD PHARMACEUTICAL LOGISTICS MARKET
- 9.4.5. REGIONAL ANALYSIS
  - 9.4.5.1. LATIN AMERICA
  - 9.4.5.1.1. LATIN AMERICA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES
  - 9.4.5.2. MIDDLE EAST & AFRICA
  - 9.4.5.2.1. MIDDLE EAST & AFRICA PHARMACEUTICAL LOGISTICS MARKET SIZE & OPPORTUNITIES

10. COMPETITIVE LANDSCAPE

10.1. KEY MARKET STRATEGIES
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
- 10.2.1. AGILITY LOGISTICS
  - 10.2.1.1. COMPANY OVERVIEW
  - 10.2.1.2. PRODUCT PORTFOLIO
  - 10.2.1.3. STRENGTHS & CHALLENGES
- 10.2.2. AP MOLLER - MAERSK
  - 10.2.2.1. COMPANY OVERVIEW
  - 10.2.2.2. PRODUCT PORTFOLIO
  - 10.2.2.3. STRENGTHS & CHALLENGES
- 10.2.3. CARDINAL HEALTH
  - 10.2.3.1. COMPANY OVERVIEW
  - 10.2.3.2. PRODUCT PORTFOLIO
  - 10.2.3.3. STRENGTHS & CHALLENGES
- 10.2.4. CENCORA (AMERISOURCEBERGEN)
  - 10.2.4.1. COMPANY OVERVIEW
  - 10.2.4.2. PRODUCT PORTFOLIO
  - 10.2.4.3. STRENGTHS & CHALLENGES
- 10.2.5. CEVA LOGISTICS
  - 10.2.5.1. COMPANY OVERVIEW
  - 10.2.5.2. PRODUCT PORTFOLIO
  - 10.2.5.3. STRENGTHS & CHALLENGES
- 10.2.6. DB SCHENKER
  - 10.2.6.1. COMPANY OVERVIEW
  - 10.2.6.2. PRODUCT PORTFOLIO
  - 10.2.6.3. STRENGTHS & CHALLENGES
- 10.2.7. DEUTSCHE POST AG
  - 10.2.7.1. COMPANY OVERVIEW
  - 10.2.7.2. PRODUCT PORTFOLIO
  - 10.2.7.3. STRENGTHS & CHALLENGES
- 10.2.8. DSV
  - 10.2.8.1. COMPANY OVERVIEW
  - 10.2.8.2. PRODUCT PORTFOLIO
  - 10.2.8.3. STRENGTHS & CHALLENGES
- 10.2.9. FEDEX
  - 10.2.9.1. COMPANY OVERVIEW
  - 10.2.9.2. PRODUCT PORTFOLIO
  - 10.2.9.3. STRENGTHS & CHALLENGES
- 10.2.10. KUEHNE + NAGEL
  - 10.2.10.1. COMPANY OVERVIEW
  - 10.2.10.2. PRODUCT PORTFOLIO
  - 10.2.10.3. STRENGTHS & CHALLENGES
- 10.2.11. MARKEN (ACQUIRED BY UPS)
  - 10.2.11.1. COMPANY OVERVIEW
  - 10.2.11.2. PRODUCT PORTFOLIO
  - 10.2.11.3. STRENGTHS & CHALLENGES
- 10.2.12. MEDLINE
  - 10.2.12.1. COMPANY OVERVIEW
  - 10.2.12.2. PRODUCT PORTFOLIO
  - 10.2.12.3. STRENGTHS & CHALLENGES
- 10.2.13. SEKO LOGISTICS
  - 10.2.13.1. COMPANY OVERVIEW
  - 10.2.13.2. PRODUCT PORTFOLIO
  - 10.2.13.3. STRENGTHS & CHALLENGES
- 10.2.14. UNITED PARCEL SERVICE (UPS)
  - 10.2.14.1. COMPANY OVERVIEW
  - 10.2.14.2. PRODUCT PORTFOLIO
  - 10.2.14.3. STRENGTHS & CHALLENGES
- 10.2.15. VERSACOLD LOGISTICS SERVICES (ACQUIRED BY LINEAGE LLC)
  - 10.2.15.1. COMPANY OVERVIEW
  - 10.2.15.2. PRODUCT PORTFOLIO
  - 10.2.15.3. STRENGTHS & CHALLENGES